ARCH Venture Partners led a $13.5m funding round in TFC Therapeutics.

ARCH Venture Partners, a company that provides early-stage venture capital for technology firms in information technology, life sciences, and physical sciences, led a $13.5m funding round in TFC Therapeutics, a biotechnology company focused on developing novel biologics to target and eliminate key drivers of cancer recurrence and metastasis. Financial terms were not disclosed. "TFC is positioned to help patients fight cancer and overcome resistance to current therapies by developing biologics designed to target and eliminate a specific cell-type that may play a fundamental and causative role in metastasis and cancer recurrence," said Dr. Gillis. "Despite substantial R&D efforts and regulatory approvals of more anti-cancer therapies, new approaches to therapy are still sorely needed. I look forward to the results of ongoing work at TFC and hope that its efforts result in the development of a new and important means of therapy for cancer patients."